Insider buying
~$47K5,000 sh @ $9.38
Traded Jun 3, 2025 · filed 1 day later
Since the trade +69.4% · S&P 500 +15.7% · to Nov 20
An Immunome director paid $47K out of pocket for Immunome shares. Shares held went up 16% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
IMNM · NASDAQ · Pharmaceutical Preparations
Immunome (IMNM) · oqro.io/stocks/IMNM · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$15.69−0.92 (−5.54%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Insider buying
Traded Jun 3, 2025 · filed 1 day later
Since the trade +69.4% · S&P 500 +15.7% · to Nov 20
An Immunome director paid $47K out of pocket for Immunome shares. Shares held went up 16% with this purchase.
Insider buying
Traded Mar 26, 2025 · filed the same day
Since the trade +121.3% · S&P 500 +21.3% · to Nov 20
The CEO of Immunome paid $999K out of pocket for Immunome shares. 2 other people at Immunome bought some too, in the same month. Shares held went up 21% with this purchase.
Insider buying
Traded Mar 25, 2025 · filed 1 day later
Since the trade +125.8% · S&P 500 +19.9% · to Nov 20
An Immunome director paid $61K out of pocket for Immunome shares. 2 other people at Immunome bought some too, in the same month. Shares held went up 33% with this purchase.
Insider buying
Traded Mar 24, 2025 · filed 1 day later
Since the trade +92.5% · S&P 500 +20.2% · to Nov 20
Immunome's Chief Technology Officer paid $104K out of pocket for Immunome shares. 2 other people at Immunome bought some too, in the same month. Shares held went up 59% with this purchase.
Insider buying
Traded Mar 24, 2025 · filed 1 day later
Since the trade +92.5% · S&P 500 +20.2% · to Nov 20
An Immunome director paid $57K out of pocket for Immunome shares. 2 other people at Immunome bought some too, in the same month. Shares held went up 42% with this purchase.
Insider buying
Traded Jan 31, 2025 · filed 4 days later
Since the trade +42.3% · S&P 500 +14.6% · to Nov 20
The CEO of Immunome paid $1.16M out of pocket for Immunome shares. Shares held went up 29% with this purchase.
Traded Nov 21 – Nov 22, 2024 · largest single transaction ~$630K
Nov 21, 2024~$630K · 66K sh @ $9.54
DetailsOfficial recordInsider buying
Traded Nov 21, 2024 · filed 4 days later
Since the trade +66.6% · S&P 500 +16.2% · to Nov 20
Immunome's Chief Technology Officer paid $198K out of pocket for Immunome shares. 2 other people at Immunome bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Nov 21, 2024 · filed 4 days later
Since the trade +66.6% · S&P 500 +16.2% · to Nov 20
Immunome's Chief Medical Officer paid $150K out of pocket for Immunome shares. 2 other people at Immunome bought some too, in the same month. It was the first purchase in over a year.
Nov 22, 2024~$332K · 34K sh @ $9.78
DetailsOfficial record0 open-market purchases and 0 open-market sales by insiders of IMNM between Feb 1, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 9, 2026. The data provider lists the next release for Mar 1, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 9, 2026 | None | None | None |
| Aug 11, 2026 | None | None | None |
| May 12, 2026 | None | None | None |
| Mar 3, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies